Patrick Herron

The ‘author’ of Be Somebody is Lester, a ventriloquist puppet with a checkered past employing a confrontational approach to the mantra that we can all ‘be somebody.’

Lester is Patrick Herron’s heteronym, his richly detailed character-author. Herron is a poet and the creator of the proximate site, a work of interactive art that explores the changes in interpersonal distances brought by the internet age. Be Somebody represents Herron’s most conceptual and wide-ranging work to date.

In Be Somebody, Lester/Herron casts authorship and identity as existential quagmires. Through the voice of a ventriloquist dummy that in turn speaks in a wide range of poetic styles, Be Somebody challenges the notion that a poet must ‘find’ his ‘voice.’ Many of the procedural techniques Herron uses to construct the poems are algorithmic processes gone awry, thus blurring the borders between human and computer and further subverting the concept that we are separate as individuals from one another.

Through Be Somebody Herron has crafted a stunning critique of the alienation engendered by the dubious projections of familiarity and personalization promised by the myriad voices of the Internet, demonstrating the manipulative power of language when wielded as a technology of control. Herron is indeed an
ambitious poet and one worth watching.

While many text mining projects emphasize retrieval and extraction, text mining can be leveraged to discover new and previously unknown infor­mation. Nowhere is the potential more apparent than in pharmacogenomics-based drug discovery. Text mining can help pharmaceutical researchers reduce the vast information overload hindering pharmacogenomics-based drug discovery because it can aid in the generation of rich novel information from large collections of diverse scientific literature and research data. However the pharmaceutical industry appears to be reluctant to innovate bleeding-edge text mining technologies for drug discovery. The present book re-frames text mining as an approach to automate the generation of novel and interesting information, reviews successful exemplary text mining appli­cations, and examines a case study of a leading pharma­ceutical company within the book's proposed novelty-generation paradigm. The present book is written for a wide range of professionals and scholars, not only for infor­mation scientists, industry analysts, and pharmaceutical executives, but also for those interested in innovation studies and the automated acceleration of discovery.

Background: The Context and Purpose of the Study Over the last decade China has emerged as a major producer of scientific publications, currently ranking second behind the US. During that time Chinese strategic policy initiatives have placed indigenous innovation at the heart of its economy while focusing internal R&D investments and the attraction of foreign investment in nanotechnology as one of their four top areas. China’s scientific research publication and nanotechnology research publication production has reached a rank of second in the world, behind only the US. Despite these impressive gains, some scholars argue that the quality of Chinese nanotech research is inferior to US research quality due to lower overall times cited rates, suggesting that the US is still the world leader. We combine citation analysis, text mining, mapping, and data visualization to gauge the development and application of nanotechnology in China, particularly in biopharmananotechnology, and to measu...

The present study explored dichotomic classification methods for medical diagnosis data through three experiments. A first experiment run in Weka used four different classification schemes on two different sets of medical test data thus permitting comparison of each scheme’s performance. A second experiment tested the application of attribute selection, information gain, and boosting to Weka’s support vector classification scheme (SMO). Finally, in the third experiment when a cost matrix was applied to breast cancer diagnostic data, false negatives were effectively reduced to under one percent while overall accuracy was slightly improved. The first experiment suggests that SMO may classify better than J48, IBk and Naïve Bayes with respect to medical test data from the UCI repository. The data of the first experiment also suggests that support vector classification-based diagnosis outperforms manual diagnosis of fine needle aspirate results. While the second experiment showed no enha...

Revision with unchanged content. While many text mining projects emphasize retrieval and extraction, text mining can be leveraged to discover new and previously unknown infor­mation. Nowhere is the potential more apparent than in pharmacogenomics-based drug discovery. Text mining can help pharmaceutical researchers reduce the vast information overload hindering pharmacogenomics-based drug discovery because it can aid in the generation of rich novel information from large collections of diverse scientific literature and research data. However the pharmaceutical industry appears to be reluctant to innovate bleeding-edge text mining technologies for drug discovery. The present book re-frames text mining as an approach to automate the generation of novel and interesting information, reviews successful exemplary text mining appli­cations, and examines a case study of a leading pharma­ceutical company within the book’s proposed novelty-generation paradigm. The present book is written for ...

THE CONTEXT AND PURPOSE OF THE STUDY: Over the last decade China has emerged as a major producer of scientific publications, currently ranking second behind the US. During that time Chinese strategic policy initiatives have placed indigenous innovation at the heart of its economy while focusing internal R&D investments and the attraction of foreign investment in nanotechnology as one of their four top areas. China's scientific research publication and nanotechnology research publication production has reached a rank of second in the world, behind only the US. Despite these impressive gains, some scholars argue that the quality of Chinese nanotech research is inferior to US research quality due to lower overall times cited rates, suggesting that the US is still the world leader. We combine citation analysis, text mining, mapping, and data visualization to gauge the development and application of nanotechnology in China, particularly in biopharmananotechnology, and to measure the ...

© 2017 OSI2017 Research Universities Stakeholder Group. This open access article is distributed under the Creative Commons Attribution 4.0 International License. This document reflects the combined input of the authors listed here (in alphabetical order by last name) as well as contributions from other OSI2017 delegates. The findings and recommendations expressed herein do not necessarily reflect the opinions of the individual authors listed here, nor their agencies, trustees, officers, or staff. Research Universities Stakeholder Report

The duality of information overload and underload is a defining issue of our age. Scholarly information is abundant but not universally accessible to all scholars and learners, thereby hindering or prohibiting equitable engagement in ongoing scholarly conversations. Access is a core aspect of the issue of overload and underload—both access to research materials and access to venues where one can contribute to the scholarly corpus—but it is not the only aspect. Our group agreed that the problem of overload is preferable to that of underload; however, the dual nature of the issue makes that conclusion more nuanced, dynamic, and situational. In this report we explore the many factors and causes of information overload and underload and also develop ideas for solutions. A summary of the issues is provided.OSI2016 Workgroup QuestionInformation underload occurs when we don’t have access to the information we need (for a variety of reasons, including cost)—researchers based at smaller inst...

Information underload occurs when we don’t have access to the information we need (for a variety of reasons, including cost) —researchers based at smaller institutions and in the global periphery, policymakers, and the general public, particularly with regard to medical research. Overload occurs when we can access everything but are simply overwhelmed by the torrent of information available (not all of which is equally valuable). Are these issues two sides of the same coin? In both cases, how can we work together to figure out how to get people the information they need? Can we? How widespread are these issues? What are the economic and research consequences of information underload and overload?

THE CONTEXT AND PURPOSE OF THE STUDY: Over the last decade China has emerged as a major producer of scientific publications, currently ranking second behind the US. During that time Chinese strategic policy initiatives have placed indigenous innovation at the heart of its economy while focusing internal R&D investments and the attraction of foreign investment in nanotechnology as one of their four top areas. China's scientific research publication and nanotechnology research publication production has reached a rank of second in the world, behind only the US. Despite these impressive gains, some scholars argue that the quality of Chinese nanotech research is inferior to US research quality due to lower overall times cited rates, suggesting that the US is still the world leader. We combine citation analysis, text mining, mapping, and data visualization to gauge the development and application of nanotechnology in China, particularly in biopharmananotechnology, and to measure the ...

This paper presents an analysis of the role of US National Nanotechnology Initiative’s Federal funding in the
takeoff of nanobiotechnology and nanomedicine. Our comparative analysis of leading nanobiotechnology and
nanomedicine scientists funded by the National Cancer Institute highlights the programmatic efforts of the NCI’s
Alliance for Nanotechnology in Cancer beginning in 2005. We use a data science approach combining web data
extraction, bibliometrics and social network analysis to identify leading nanomedicine and nanobiotechnology
scientists and profile their research and commercialization efforts. By coupling leading nanomedicine researchers
profiles to NNI Federal funding data we discover and document the relative importance of the US National Cancer
Institute’s Alliance for Nanotechnology in Cancer (NCI Alliance) to the takeoff of nanomedicine. The NCI appears
to be achieving its stated goal of contributing to both the scientific and commercial infrastructure of translational
nanomedicine. Using Gilsing et al.’s innovation network embeddedness model from 2008 we find that the creation
and strategic placement of NCI Alliance Centers at critical positions in the Alliance network has enhanced the
ability of the NCI to build a sustainable architecture for nanomedicine and foster potentially disruptive pioneering
innovation.

ABSTRACTBackground: The Context and Purpose of the StudyOver the last decade China has emerged as a major producer of scientific publications, currently ranking second behind the US. During that time Chinese strategic policy initiatives have placed indigenous innovation at the heart of its economy while focusing internal R&D investments and the attraction of foreign investment in nanotechnology as one of their four top areas. China’s scientific research publication and nanotechnology research publication production has reached a rank of second in the world, behind only the US. Despite these impressive gains, some scholars argue that the quality of Chinese nanotech research is inferior to US research quality due to lower overall times cited rates, suggesting that the US is still the world leader. We combine citation analysis, text mining, mapping, and data visualization to gauge the development and application of nanotechnology in China, particularly in biopharmananotechnology, and to measure the impact of Chinese policy on nanotechnology research production.Results, the main findingsOur text mining-based methods provide results that counter existing claims about Chinese nanotechnology research quality. Due in large part to its strategic innovation policy, China’s output of nanotechnology publications is on pace to surpass US production in or around 2012.A closer look at Chinese nanotechnology research literature reveals a large increase in research activity in China’s biopharmananotechnology research since the implementation in January, 2006 of China’s Medium & Long Term Scientific and Technological Development Plan Guidelines for the period 2006-2020 (“MLP”). Since the implementation of the MLP, China has enjoyed a great deal of success producing bionano research findings while attracting a great deal of foreign investment from pharmaceutical corporations setting up advanced drug discovery operations. Given the combination of current scientific production growth as well as economic growth, a relatively low scientific capacity, and the ability of its policy to enhance such trends, China is in some sense already the new world leader in nanotechnology. Further, the Chinese national innovation system may be the new standard by which other national S&T policies should be measured.